A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.

ClinicalTrials.gov ID: NCT07215702

Public ClinicalTrials.gov record NCT07215702. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 2, 2026, 3:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IIa, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Assess the Efficacy, Safety, and Tolerability of AZD4144 in Participants With Sepsis-associated Acute Kidney Injury (SERENIA)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will enroll adults aged 18 to 80 years diagnosed with sepsis due to a suspected or confirmed bacterial infection, within 7 days of being admitted to the hospital, and who have also developed acute kidney injury within 72 hours of the onset of sepsis. Eligible participants will be randomly assigned to receive either AZD4144 or a placebo intravenously once daily for the number of days specified in the CSP. During this Treatment Period, participants will undergo daily safety monitoring, as well as blood and urine sample collection and other assessments. After the Treatment Period, participants will continue to be monitored for safety and other assessments during each additional day they remain hospitalized (if applicable) as well as during up to 2 follow up visits after discharge. The main goal is to compare specific kidney function measurements between those participants receiving AZD4144 and those receiving the placebo.

Study identification

NCT ID: NCT07215702
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: AstraZeneca; Industry
Enrollment: 124 participants

Conditions and interventions

Conditions

Interventions

AZD4144 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 80 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 9, 2026
Primary completion: Feb 10, 2027
Completion: Feb 10, 2027
Last update posted: Jul 29, 2026

2026 – 2027

United States locations

U.S. sites: 16
U.S. states: 12
U.S. cities: 14

Facility	City	State	ZIP	Site status
Research Site	Tucson	Arizona	85719	Not yet recruiting
Research Site	Newport Beach	California	92663	Recruiting
Research Site	Kansas City	Kansas	66160	Recruiting
Research Site	Baltimore	Maryland	21211	Not yet recruiting
Research Site	Boston	Massachusetts	02115	Recruiting
Research Site	Detroit	Michigan	48202	Recruiting
Research Site	The Bronx	New York	10451	Recruiting
Research Site	The Bronx	New York	10461	Recruiting
Research Site	The Bronx	New York	10467	Recruiting
Research Site	Chapel Hill	North Carolina	27519	Not yet recruiting
Research Site	Winston-Salem	North Carolina	27157	Recruiting
Research Site	Corvallis	Oregon	97330	Withdrawn
Research Site	Philadelphia	Pennsylvania	19140	Not yet recruiting
Research Site	Pittsburgh	Pennsylvania	15213	Not yet recruiting
Research Site	Charleston	South Carolina	29402	Recruiting
Research Site	Salt Lake City	Utah	84107	Withdrawn

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 56 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07215702, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 29, 2026 · Synced Sep 2, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07215702 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →